BI 765250

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyPsoriasis

Phase 1

A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin

CompletedNCT05151653

Boehringer IngelheimHealthy

Start: 2022-01-26End: 2024-09-13Updated: 2025-01-22

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

CompletedNCT05728489

Boehringer IngelheimPsoriasis

Start: 2023-04-27End: 2025-02-24Updated: 2025-03-07